Biocept receives 150,000 samples for COVID-19 testing; completes relocation

Biocept Inc (NASDAQ:BIOC) (FRA:B003) provided a business update Monday, saying it had successfully relocated to its new corporate headquarters and molecular laboratory facility in San Diego, USA.  The molecular diagnostics company also said it had received more than 150,000 samples for COVID-19 (coronavirus) RT-PCR testing to date and has continued to report the vast majority of results to customers within 48 hours of receiving a sample.  READ: Biocept's Target Selector liquid biopsy shown to detect HER2 protein in breast cancer patients at San Antonio event "All clinical operations at the new facility are fully functioning, including our newly designed state-of-art CLIA-certified and CAP-accredited laboratory," said the company's chief financial officer and senior vice-president of operations Tim Kennedy.  "We are pleased with the smooth transition, and our ability to seamlessly continue serving physicians and patients with both oncology and COVID-19 testing.  "Our new facility was designed specifically to align with our commercial, development and administrative needs, with the bonus of an expected 20% annualized reduction in rent and other facility costs." Contact the author at giles@proactiveinvestors.com